{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:17:16Z","timestamp":1784614636864,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocr Pathol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12022-025-09887-8","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:00:06Z","timestamp":1762149606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy"],"prefix":"10.1007","volume":"36","author":[{"given":"Louis","family":"de Mestier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Apostolidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Koumarianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Riechelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K.","family":"Bergsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cingarlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagufta","family":"Shaheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Crona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kreutzfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Mosalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taymeyah","family":"Al-Toubah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Cros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Strosberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"9887_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, et al (2017) Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 3:1335\u20131342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589","journal-title":"JAMA Oncol"},{"key":"9887_CR2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0364","author":"B Nu\u00f1ez-Valdovinos","year":"2018","unstructured":"Nu\u00f1ez-Valdovinos B, Carmona\u2010Bayonas A, Jimenez\u2010Fonseca P, et al (2018) Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real\u2010World Data from the Spanish Tumor Registry (R\u2010GETNE). The Oncologist 23:422\u2013432. https:\/\/doi.org\/10.1634\/theoncologist.2017-0364"},{"key":"9887_CR3","doi-asserted-by":"publisher","first-page":"100510","DOI":"10.1016\/j.lanepe.2022.100510","volume":"23","author":"BE White","year":"2022","unstructured":"White BE, Rous B, Chandrakumaran K, et al (2022) Incidence and survival of neuroendocrine neoplasia in England 1995\u20132018: A retrospective, population-based study. Lancet Reg Health - Eur 23:100510. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100510","journal-title":"Lancet Reg Health - Eur"},{"key":"9887_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi G, Mete O, Uccella S, et al (2022) Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 33:115\u2013154. https:\/\/doi.org\/10.1007\/s12022-022-09708-2","journal-title":"Endocr Pathol"},{"key":"9887_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.dld.2020.02.011","volume":"52","author":"L de Mestier","year":"2020","unstructured":"de Mestier L, Lepage C, Baudin E, et al (2020) Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis 52:473\u2013492. https:\/\/doi.org\/10.1016\/j.dld.2020.02.011","journal-title":"Dig Liver Dis"},{"key":"9887_CR6","doi-asserted-by":"publisher","unstructured":"Kos-Kud\u0142a B, Casta\u00f1o JP, Denecke T, et al (2023) European Neuroendocrine Tumor Society 2023 Guidance Paper for Non\u2010functioning Pancreatic Neuroendocrine Tumours. J Neuroendocrinol e13343. https:\/\/doi.org\/10.1111\/jne.13343","DOI":"10.1111\/jne.13343"},{"key":"9887_CR7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.ejca.2015.04.005","volume":"51","author":"L-M Dilz","year":"2015","unstructured":"Dilz L-M, Denecke T, Steffen IG, et al (2015) Streptozocin\/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer 51:1253\u20131262. https:\/\/doi.org\/10.1016\/j.ejca.2015.04.005","journal-title":"Eur J Cancer"},{"key":"9887_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000498887","volume":"108","author":"L de Mestier","year":"2019","unstructured":"de Mestier L, Walter T, Brixi H, et al (2019) Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses. Neuroendocrinology 108:343\u2013353. https:\/\/doi.org\/10.1159\/000498887","journal-title":"Neuroendocrinology"},{"key":"9887_CR9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","volume":"41","author":"PL Kunz","year":"2023","unstructured":"Kunz PL, Graham NT, Catalano PJ, et al (2023) Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol 41:1359\u20131369. https:\/\/doi.org\/10.1200\/JCO.22.01013","journal-title":"J Clin Oncol"},{"key":"9887_CR10","doi-asserted-by":"publisher","first-page":"R391","DOI":"10.1530\/ERC-20-0227","volume":"27","author":"L de Mestier","year":"2020","unstructured":"de Mestier L, Couvelard A, Blazevic A, et al (2020) Critical appraisal of MGMT in digestive NET treated with alkylating agents. Endocr Relat Cancer 27:R391\u2013R405. https:\/\/doi.org\/10.1530\/ERC-20-0227","journal-title":"Endocr Relat Cancer"},{"key":"9887_CR11","doi-asserted-by":"publisher","first-page":"R121","DOI":"10.1530\/ERC-20-0473","volume":"28","author":"KI Alexandraki","year":"2021","unstructured":"Alexandraki KI, Spyroglou A, Kykalos S, et al (2021) Changing biological behaviour of NETs during the evolution of the disease: progress on progression. Endocr Relat Cancer 28:R121\u2013R140. https:\/\/doi.org\/10.1530\/ERC-20-0473","journal-title":"Endocr Relat Cancer"},{"key":"9887_CR12","doi-asserted-by":"publisher","first-page":"175883592311793","DOI":"10.1177\/17588359231179310","volume":"15","author":"P Bourdeleau","year":"2023","unstructured":"Bourdeleau P, Couvelard A, Ronot M, et al (2023) Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms. Ther Adv Med Oncol 15:175883592311793. https:\/\/doi.org\/10.1177\/17588359231179310","journal-title":"Ther Adv Med Oncol"},{"key":"9887_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1159\/000504392","volume":"110","author":"J Botling","year":"2020","unstructured":"Botling J, Lamarca A, Bajic D, et al (2020) High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors. Neuroendocrinology 110:891\u2013898. https:\/\/doi.org\/10.1159\/000504392","journal-title":"Neuroendocrinology"},{"key":"9887_CR14","doi-asserted-by":"publisher","first-page":"e240321","DOI":"10.1530\/ERC-24-0321","volume":"32","author":"P Bourdeleau","year":"2025","unstructured":"Bourdeleau P, Pokossy-Ep\u00e9e J, Hentic O, et al (2025) Temporal increase in Ki-67 index in patients with pancreatic neuroendocrine tumours. Endocr Relat Cancer 32:e240321. https:\/\/doi.org\/10.1530\/ERC-24-0321","journal-title":"Endocr Relat Cancer"},{"key":"9887_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/jne.70040","author":"K Mollazadegan","year":"2025","unstructured":"Mollazadegan K, Botling J, Skogseid B, et al (2025) The impact of re-characterizing metastatic pancreatic neuroendocrine tumors: A prospective study. J Neuroendocrinol e70040. https:\/\/doi.org\/10.1111\/jne.70040","journal-title":"J Neuroendocrinol e70040"},{"key":"9887_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12022-024-09827-y","volume":"35","author":"A Kasajima","year":"2024","unstructured":"Kasajima A, Pfarr N, Mayr E-M, et al (2024) Rapid Evolution of Metastases in Patients with Treated G3 Neuroendocrine Tumors Associated with NEC-Like Transformation and TP53 Mutation. Endocr Pathol 35:313\u2013324. https:\/\/doi.org\/10.1007\/s12022-024-09827-y","journal-title":"Endocr Pathol"},{"key":"9887_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12022-024-09844-x","volume":"35","author":"O Mete","year":"2024","unstructured":"Mete O (2024) Insights into Biologic Evolution of Grade 3 Neuroendocrine Tumors Reflect Classification Challenges. Endocr Pathol 35:311\u2013312. https:\/\/doi.org\/10.1007\/s12022-024-09844-x","journal-title":"Endocr Pathol"},{"key":"9887_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s12022-024-09835-y","volume":"35","author":"NM Joseph","year":"2024","unstructured":"Joseph NM, Umetsu SE, Kim GE, et al (2024) Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53. Endocr Pathol 35:325\u2013337. https:\/\/doi.org\/10.1007\/s12022-024-09835-y","journal-title":"Endocr Pathol"},{"key":"9887_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","volume":"580","author":"M Touat","year":"2020","unstructured":"Touat M, Li YY, Boynton AN, et al (2020) Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580:517\u2013523. https:\/\/doi.org\/10.1038\/s41586-020-2209-9","journal-title":"Nature"},{"issue":"2","key":"9887_CR20","doi-asserted-by":"publisher","first-page":"S701","DOI":"10.1016\/S0923-7534(23)01264-4","volume":"34","author":"L de Mestier","year":"2023","unstructured":"de Mestier L, Cohen D, Masliah Planchon J, et al (2023) Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well differentiated pancreatic neuroendocrine tumors (1182O). Ann Oncol 34 (suppl.2):S701\u2013S710. https:\/\/doi.org\/10.1016\/S0923-7534(23)01264-4","journal-title":"Ann Oncol"},{"key":"9887_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/path.6348","volume":"264","author":"S Backman","year":"2024","unstructured":"Backman S, Botling J, Nord H, et al (2024) The evolutionary history of metastatic pancreatic neuroendocrine tumours reveals a therapy driven route to high-grade transformation. J Pathol 264:357\u2013370. https:\/\/doi.org\/10.1002\/path.6348","journal-title":"J Pathol"},{"key":"9887_CR22","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1434","author":"G Crisafulli","year":"2022","unstructured":"Crisafulli G, Sartore-Bianchi A, Lazzari L, et al (2022) Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discov candisc.1434.2021. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1434","journal-title":"Cancer Discov candisc"},{"key":"9887_CR23","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1002\/cncr.32883","volume":"126","author":"JM Mehnert","year":"2020","unstructured":"Mehnert JM, Bergsland E, O\u2019Neil BH, et al (2020) Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer 126:3021\u20133030. https:\/\/doi.org\/10.1002\/cncr.32883","journal-title":"Cancer"},{"key":"9887_CR24","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-19-3014","volume":"26","author":"J Strosberg","year":"2020","unstructured":"Strosberg J, Mizuno N, Doi T, et al (2020) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clin Cancer Res 26:2124\u20132130. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3014","journal-title":"Clin Cancer Res"},{"key":"9887_CR25","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0382","author":"JC Yao","year":"2021","unstructured":"Yao JC, Strosberg J, Fazio N, et al (2021) Spartalizumab in metastatic, well\/poorly-differentiated neuroendocrine neoplasms. Endocr Relat Cancer ERC-20-0382.R1. https:\/\/doi.org\/10.1530\/ERC-20-0382","journal-title":"Endocr Relat Cancer ERC"},{"key":"9887_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"9887_CR27","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1158\/1078-0432.CCR-20-0621","volume":"26","author":"O Klein","year":"2020","unstructured":"Klein O, Kee D, Markman B, et al (2020) Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. Clin Cancer Res 26:4454\u20134459. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0621","journal-title":"Clin Cancer Res"},{"key":"9887_CR28","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","volume":"26","author":"SP Patel","year":"2020","unstructured":"Patel SP, Othus M, Chae YK, et al (2020) A Phase II Basket Trial of Dual Anti\u2013CTLA-4 and Anti\u2013PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res 26:2290\u20132296. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3356","journal-title":"Clin Cancer Res"},{"key":"9887_CR29","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.21.02583","volume":"40","author":"F Morano","year":"2022","unstructured":"Morano F, Raimondi A, Pagani F, et al (2022) Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6 -Methylguanine\u2013DNA Methyltransferase\u2013Silenced Metastatic Colorectal Cancer: The MAYA Trial. J Clin Oncol 40:1562\u20131573. https:\/\/doi.org\/10.1200\/JCO.21.02583","journal-title":"J Clin Oncol"},{"key":"9887_CR30","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature24673","volume":"552","author":"G Germano","year":"2017","unstructured":"Germano G, Lamba S, Rospo G, et al (2017) Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552:116\u2013120. https:\/\/doi.org\/10.1038\/nature24673","journal-title":"Nature"},{"key":"9887_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000503392","volume":"110","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Barriuso J, McNamara MG, et al (2020) Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration. Neuroendocrinology 110:155\u2013157. https:\/\/doi.org\/10.1159\/000503392","journal-title":"Neuroendocrinology"},{"key":"9887_CR32","doi-asserted-by":"publisher","first-page":"S755","DOI":"10.1016\/j.annonc.2024.08.1213","volume":"35","author":"E Trevisani","year":"2024","unstructured":"Trevisani E, Cingarlini S, Taboada RG, et al (2024) 1154P Prospective multinational evaluation of alkylating-induced hypermutation in neuroendocrine neoplasms (NEN): Clinical and molecular profiles associated with response to immune checkpoint inhibitors (CPI). Ann Oncol 35:S755. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1213","journal-title":"Ann Oncol"},{"key":"9887_CR33","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1158\/1078-0432.CCR-18-1892","volume":"25","author":"S Indraccolo","year":"2019","unstructured":"Indraccolo S, Lombardi G, Fassan M, et al (2019) Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma. Clin Cancer Res 25:1828\u20131837. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1892","journal-title":"Clin Cancer Res"},{"key":"9887_CR34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/modpathol.2008.177","volume":"22","author":"A Couvelard","year":"2009","unstructured":"Couvelard A, Deschamps L, Ravaud P, et al (2009) Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol 22:273\u2013281. https:\/\/doi.org\/10.1038\/modpathol.2008.177","journal-title":"Mod Pathol"},{"key":"9887_CR35","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s42003-020-01479-y","volume":"3","author":"A Di Domenico","year":"2020","unstructured":"Di Domenico A, Pipinikas CP, Maire RS, et al (2020) Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression. Commun Biol 3:740. https:\/\/doi.org\/10.1038\/s42003-020-01479-y","journal-title":"Commun Biol"}],"container-title":["Endocrine Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09887-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12022-025-09887-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12022-025-09887-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:26:02Z","timestamp":1767860762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12022-025-09887-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9887"],"URL":"https:\/\/doi.org\/10.1007\/s12022-025-09887-8","relation":{"references":[{"id-type":"doi","id":"10.1634\/theoncologist.2017-0364","asserted-by":"subject"}]},"ISSN":["1046-3976","1559-0097"],"issn-type":[{"value":"1046-3976","type":"print"},{"value":"1559-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LdM: consulting fees (personal) from Novartis, Boehringer Ingelheim, Esteve, Ipsen, Mayoly, Servier, Viatris. Research fees (institutional) from Boehringer Ingelheim, Esteve, Mayoly-\tTH: Consulting fees (personal) from Biomea Fusion, Boehringer-Ingelheim, Curium, Exelixis, TerSera. Consulting fees (institutional) from Abdera Therapeutics, Camurus, Crinetics, Ipsen, ITM, Novartis, Perspective Therapeutics. Research fees (institutional) from AAA\/Novartis, Camurus, Crinetics, ITM, RayzeBio, Perspective Therapeutics, Thermo Fisher Scientific-\tLA: Consulting fees (personal) from Ipsen, Novartis, Deciphera. Travel expenses from Ipsen, Novartis, Boehringer Ingelheim, ITM. Research fees (institutional) from Ipsen, Novartis-\tAK: Consulting fees from Ipsen, MSD, BMS, AstraZeneca, Integris, Servier, Genesis-\tJH: Speaker\u00b4s Bureau Ipsen, Novartis, ADACAP, Lilly, Eisai, Bayer, Pfizer, Angelini.-\tRR: consulting fees (personal) from Ipsen, MSD. Research fees (institutional) from RazeBio, Crinetics, Exelixs-\tEB: research fees (institutional) from Boehringer Ingelheim, Merck, RayzeBio-\tSS: Consulting fee (personal) from Crinetics, Exelixis-\tSK: Consulting fee (personal) from Roche-\tJC: consulting fees (personal) from Novartis and Boehringer Ingelheim-\tJS: consulting fees (personal) from Exelixis and Boehringer Ingelheim-\tSC, JC, OM, TAT: None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed according to the Helsinki convention and following Institutional Review Board approval (CEERB Paris Nord, IRB no. 00006477-15-073). The study protocol was approved by the ethics or audit committees at each institution, where required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}],"article-number":"42"}}